229 related articles for article (PubMed ID: 19757306)
21. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.
Hoy SM; McKeage K
Drugs; 2010 Oct; 70(14):1819-29. PubMed ID: 20836575
[TBL] [Abstract][Full Text] [Related]
22. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
Teachey DT; Grupp SA; Brown VI
Br J Haematol; 2009 Jun; 145(5):569-80. PubMed ID: 19344392
[TBL] [Abstract][Full Text] [Related]
23. Temsirolimus.
Schulze M; Stock C; Zaccagnini M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2014; 201():393-403. PubMed ID: 24756806
[TBL] [Abstract][Full Text] [Related]
24. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
25. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
Chapuis N; Tamburini J; Green AS; Willems L; Bardet V; Park S; Lacombe C; Mayeux P; Bouscary D
Leukemia; 2010 Oct; 24(10):1686-99. PubMed ID: 20703258
[TBL] [Abstract][Full Text] [Related]
26. mTOR signaling and drug development in cancer.
Dancey J
Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
[TBL] [Abstract][Full Text] [Related]
27. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
[TBL] [Abstract][Full Text] [Related]
28. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
29. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
30. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
[TBL] [Abstract][Full Text] [Related]
31. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
32. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers.
Younes A
Autophagy; 2008 Jul; 4(5):707-9. PubMed ID: 18469512
[TBL] [Abstract][Full Text] [Related]
34. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
35. Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma.
Rosich L; Colomer D; Roue G
Autophagy; 2013 Jan; 9(1):115-7. PubMed ID: 23079699
[TBL] [Abstract][Full Text] [Related]
36. Targeting mTOR pathways in human malignancies.
Fasolo A; Sessa C
Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
38. Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR?
Rule S
Am J Hematol; 2010 May; 85(5):313-4. PubMed ID: 20425793
[No Abstract] [Full Text] [Related]
39. The mTOR pathway: a new target in cancer therapy.
Ciuffreda L; Di Sanza C; Incani UC; Milella M
Curr Cancer Drug Targets; 2010 Aug; 10(5):484-95. PubMed ID: 20384580
[TBL] [Abstract][Full Text] [Related]
40. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]